Karyopharm Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 5, 2024
KPTI$0.04-27.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenues: | ||||
| Product revenue, net | $29,516 | $30,207 | $83,554 | $86,955 |
| License and other revenue | 9,267 | 5,802 | 31,141 | 25,331 |
| Total revenue | 38,783 | 36,009 | 114,695 | 112,286 |
| Operating expenses: | ||||
| Cost of sales | 1,300 | 911 | 4,676 | 3,456 |
| Research and development | 36,134 | 35,553 | 109,930 | 99,369 |
| Selling, general and administrative | 27,632 | 30,805 | 88,251 | 101,193 |
| Total operating expenses | 65,066 | 67,269 | 202,857 | 204,018 |
| Loss from operations | (26,283) | (31,260) | (88,162) | (91,732) |
| Other income (expense): | ||||
| Interest income | 1,832 | 2,750 | 5,918 | 8,423 |
| Interest expense | (11,385) | (6,073) | (26,218) | (17,615) |
| Gain on extinguishment of debt | — | — | 44,702 | — |
| Other income (expense), net | 3,792 | 89 | 18,284 | (145) |
| Total other income (expense), net | (5,761) | (3,234) | 42,686 | (9,337) |
| Loss before income taxes | (32,044) | (34,494) | (45,476) | (101,069) |
| Income tax provision | (28) | (12) | (166) | (193) |
| Net loss | $(32,072) | $(34,506) | $(45,642) | $(101,262) |
| Basic net loss per share (Note 7) | $(0.26) | $(0.30) | $(0.38) | $(0.89) |
| Diluted net loss per share (Note 7) | $(0.26) | $(0.30) | $(0.69) | $(0.89) |
| Weighted-average number of common shares outstanding used to compute basic net loss per share | 125,010 | 114,401 | 120,513 | 114,033 |
| Weighted-average number of common shares outstanding used to compute diluted net loss per share | 125,010 | 114,401 | 126,606 | 114,033 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.